Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Launched by CALITHERA BIOSCIENCES, INC · Feb 24, 2014
Trial Information
Current as of July 04, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Inclusion criteria
- • Advanced malignancy that is relapsed and/or refractory to all available therapies that will confer clinical benefit. Newly diagnosed patients who refuse standard treatment regimens are also eligible
- • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
- • Life Expectancy of at least 3 months
- • Adequate hepatic, renal, cardiac, and hematologic function
- • Measurable disease by RECIST criteria
- • Ability to provide written informed consent in accordance with federal, local, and institutional guidelines
- • Exclusion Criteria
- • Any other current or previous malignancy
- • Chemotherapy, radiation therapy, hormonal therapy, immunotherapy or biological therapy, or investigational agent within 21 days
- • Unable to receive medications oral medications
- • Major surgery within 28 days before Cycle 1 Day 1
- • Active infection requiring within 2 weeks prior to first dose of study drug
- • Patients who have HIV, Hepatitis A, B or C or CMV reactivation
- • Significant neurotoxicity/neuropathy (Grade 3 or higher) within 14 days of first dose of study drug
- • Conditions that could interfere with treatment or protocol-related procedures
About Calithera Biosciences, Inc
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cancer and other serious diseases. With a commitment to advancing precision medicine, Calithera leverages its expertise in small molecule drug discovery and development to target pivotal pathways in tumor biology. The company aims to address unmet medical needs through its robust pipeline of investigational drugs, emphasizing a scientific approach driven by rigorous research and collaboration. By fostering partnerships and utilizing cutting-edge technologies, Calithera is dedicated to improving patient outcomes and transforming the landscape of cancer treatment.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
New York, New York, United States
Boston, Massachusetts, United States
New York, New York, United States
Stanford, California, United States
Boston, Massachusetts, United States
San Francisco, California, United States
Houston, Texas, United States
Boston, Massachusetts, United States
Sarasota, Florida, United States
Nashville, Tennessee, United States
Philadelphia, Pennsylvania, United States
Atlanta, Georgia, United States
Bethesda, Maryland, United States
Patients applied
Trial Officials
Samuel Whiting, MD, PhD
Study Director
Calithera Biosciences, Inc
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials